Geneoscopy and Exact Sciences have reached a settlement resolving all pending district court litigation in Delaware concerning Geneoscopy’s ColoSense colorectal cancer screening test. The court dismissed all claims and counterclaims, including Exact Sciences’ patent infringement claims and allegations of false or misleading advertising. The settlement includes no admission of liability or wrongdoing by either company, and its financial and other terms remain confidential.
The resolution follows several victories for Geneoscopy at the US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB). In July 2025, the PTAB found all 20 challenged claims of an Exact Sciences patent unpatentable as obvious. In February 2026, it reached the same conclusion regarding 10 challenged claims of another patent. According to Geneoscopy, the Patent Office determined that every patent claim Exact Sciences asserted against the company in the litigation was invalid.

